How-To Guides
2 guidesHow to Choose Between Sertraline and Fluvoxamine for Drug-Naive OCD
How should clinicians choose between sertraline and fluvoxamine when initiating SSRI treatment for a drug-naive patient with OCD?
How to Use Early YBOCS Change to Predict OCD SSRI Response
How can clinicians use early symptom change on the YBOCS to estimate whether a drug-naive patient with OCD will respond to an SSRI by 12 weeks?
Frequently Asked Questions
12 questions-
Yes. In this 12-week randomized study of 50 drug-naive patients with OCD, early improvement predicted 12-week response with 77.8% sensitivity and 85.7% specificity. Early improvement was defined as a 20% or greater reduction in Yale-Brown Obsessive-Compulsive Scale (YBOCS) score, and final response was defined as a 35% or greater reduction in YBOCS score at 12 weeks.
-
Early improvement was observed at 4 weeks after achieving the minimum therapeutic dose. In the study protocol, patients started at 50 mg/day, doses were escalated over a 2-week induction period to at least a therapeutic dose, and early response was then assessed during the following 4 weeks using a 20% or greater reduction in YBOCS score.
-
Sixty percent of patients (30 of 50) showed early response, defined as a 20% or greater reduction in YBOCS score at 4 weeks after reaching the minimum therapeutic dose. The number of early responders was comparable between the sertraline and fluvoxamine groups.
-
In this study, patients with early improvement were very likely to respond by 12 weeks. Of the 30 patients who showed early response, 93.3% met the study's 12-week response criterion of a 35% or greater reduction in YBOCS score (Pearson χ2 = 16.93, P = .000).
-
No. Although early improvement was predictive, lack of early response did not rule out later benefit. In this study, 40% of patients (20 of 50) did not show early response, and 8 of those 20 patients still met response criteria by 12 weeks.
-
The study found a mixed result. Fluvoxamine had a significantly higher categorical response rate than sertraline at 12 weeks (Pearson χ2 = 6.349, P = .012), but the reduction in mean YBOCS scores between the 2 groups was not significantly different (sertraline 13.80 vs fluvoxamine 11.96 at 12 weeks, P = .443).
-
Yes. The authors reported that both medications had similar side effect profiles and concluded that sertraline and fluvoxamine were equally well tolerated in this sample of drug-naive patients with OCD.
-
Participants in both groups started at 50 mg/day. By the end of the 2-week induction period, the average minimum dose reached was 95 mg/day for sertraline and 102 mg/day for fluvoxamine. The mean maximum tolerable therapeutic doses later reached were 196 mg/day for sertraline and 284 mg/day for fluvoxamine.
-
Across the full sample, OCD severity improved significantly over 12 weeks. The mean baseline YBOCS score was 23.48 ± 6.29, and the mean YBOCS score at 12 weeks was 12.88, a statistically significant reduction (P = .000).
-
No. The study found no significant difference in sociodemographic or clinical characteristics between early responders and early nonresponders. In this sample, short-term symptom change was more informative than baseline patient characteristics for estimating 12-week outcome.
-
This study suggests that a full 12-week wait may not be necessary for all patients. The authors concluded that if a patient does not show early improvement after 4 weeks at a minimum therapeutic SSRI dose, a long 12-week drug trial may not be warranted in all cases, although some early nonresponders still improved by week 12.
-
The main limitations were a small sample size and the coincidental inclusion of more patients with moderate severity of illness. The authors stated that larger studies are needed before revising current treatment expectations for OCD.
